St. Jude pipeline looks promising for future

Although the defibrillator market may be shrinking, St. Jude Medical is continuing to find ways to expand its presence in the medical device community, whether by taking some of a competitor's market share or focusing on new procedures and emerging markets.

In an investor conference call last week, St. Jude said it is focusing on technology for lower-impact heart valve and hypertension procedures. Although the fruits of those technologies may be years away, the company is still growing here-and-now as it gained three percentage points of market share in the last year from its competitors, Medtronic and Boston Scientific. According to CEO Daniel Starks, another four points could come in the next four to six years, mostly from replacement procedures.

- here's the Dow Jones article
- read the WSJ coverage

Suggested Articles

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.

Emmecell aims to make corneal transplant surgery, which can take up to a year to heal from and fails up to 20% of the time, a relic of the past.

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.